FIRST CLASS ANALYTICS ON FDA ONCOLOGY DECISIONS
✔ New FDA drug approvals updated in real-time
✔ Access in-depth analytics on 350+ oncology indications
✔ Identify FDA regulatory precedent in oncology approvals
Avoid the expense of collecting historical information on regulatory approvals and have confidence with years of reporting on-demand.
Work smarter not harder, with our 'best-in-class' software letting you login and access information from your desktop, tablet or phone.
Review the outcome of past decisions with analysis that gives specific insight into precedent, based on prior regulatory approvals.
online solution that provides market leading analytics
The availability of new drugs often means new treatment options for patients and advances in health care for the public. For this reason "innovation" is a key word throughout the pharmaceutical industry and the healthcare community. RxTROSPECT's products support drug innovation and open avenues for better decision-making to advance new drug development in America and Europe.
The leadership team at RxTROSPECT has roots that run deep in the pharmaceutical industry. They understand the process of regulatory approvals and recognize the benefit of helping companies bring their innovation to market with less effort and more confidence. That’s why in 2017 the company began designing reliable and easy-to-use products to give companies a retrospective look into decisions involving regulatory approvals.
Exploring FDA-Approved Oncology Breakthroughs
RxTROSPECT Oncology allows you to identify FDA approved, breakthrough therapy-designated, indications in seconds. Select the breakthrough filter and watch the RxTROSPECT dashboard update immediately. Interact with the charts, view details or navigate the top tabs to gain insights on everything from patient numbers to study design.
IDENTIFYING PRODUCTS BASED ON PHASE I, II AND III STUDIES
RxTROSPECT Oncology allows you to identify products or groups of products based on the approved condition (e.g. NSCLC) and identify the phase of the registration study (e.g. Phase I, II or III). View a comprehensive summary of the benefit-risk profile for each approval at the time of the FDA decision. Looking at these components together helps us to understand how one sponsor gained approval on a Phase I study, while others are approved on more traditional Phase IIIs.
The Evolution of Regulatory Efficacy Endpoints
We can use RxTROSPECT Oncology to understand how primary efficacy endpoints have evolved over time from a regulatory perspective. Explore trends for a single condition or compare multiple conditions on the same RxTROSPECT dashboard. Gain insights on 350+ FDA-approved oncology indications with ease.
RxTROSPECT have partnered with Tableau, a pioneer and leader in delivering business intelligence solutions.
This partnership with Tableau allows RxTROSPECT customers to receive a comprehensive end-to-end solution that lets them easily navigate information from a wide variety of data sources within one online platform — delivering a single version of truth. By using RxTROSPECT as the solid foundation for analytics, you bring your company a scalable, structured and secure product that lies within a reliable self-service analytics framework, allowing you to practice near real-time analysis on large sets of data.
OUR SOLUTION SUPPORTS CUSTOMERS BY ALLOWING THEM TO:
Easily access a single source of clean information to support better decision-making
Create new reports and visualizations without waiting for IT to add data sources
Add consistency to reports and presentations created through a well-governed and reliable platform
Reduce external consultancy costs and reliance on in-house IT
Enhance scalability, with a single online solution rolled out enterprise-wide
Avoid reporting errors due to changes in data sources or individual assumptions